Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Data on cancer vaccines described by S. Kang et al
October 29th, 2008
According to recent research from Seoul, South Korea, "Human papillomavirus (HPV) is a major causative agent of anogenital warts and a necessary cause of cervical cancer. This report will serve to assess the safety and immunogenicity of quadrivalent (types 6, 11, 16, and 18) HPV L1 virus-like particle (VLP) vaccine in the Korean population." "We performed a randomized, double-blind, placebo-controlled study in 176 volunteers aged 9-23 years. Using a 2:1 ratio for randomization, 117 women were assigned to quadrivalent HPV (20 mu g type 6, 40 mu g type 11, 40 mu g type 16, and 20 mu g type 18) vaccine and 59 women to placebo. Individuals received vaccine at day 1, month...
Source: Vaccine Weekly (2008-10-29)
|
